# Impact of residual moderate mitral regurgitation after transcatheter edge-to-edge repair on long-term survival: insights from a multicenter cohort study

**Authors:** Felix Ausbuettel, Georgios Chatzis, Harald Schuett, Sebastian Barth, Sebastian Kerber, Bernhard Schieffer, Christian Waechter, Ulrich Luesebrink

PMC · DOI: 10.3389/fcvm.2026.1720322 · Frontiers in Cardiovascular Medicine · 2026-02-18

## TL;DR

This study examines how residual moderate mitral regurgitation after a heart repair procedure affects long-term survival in patients.

## Contribution

The study identifies age under 65 as a key predictor of suboptimal MR reduction after transcatheter edge-to-edge repair.

## Key findings

- Residual MR of II° occurred in 12% of patients and was more common in younger, comorbid individuals.
- Age <65 years remained a significant inverse predictor of residual MR ≤ I° in multivariable analysis.
- Long-term survival did not differ significantly between patients with residual MR ≤ I° and II°.

## Abstract

Transcatheter edge-to-edge mitral valve repair (mTEER) is an established treatment for patients with mitral regurgitation (MR) at prohibitive surgical risk. However, predictors of optimal MR reduction remain insufficiently defined.

We retrospectively analyzed all patients who underwent mTEER treatment at four German cardiac centers between 2011 and 2022. Patients were categorized by residual MR ≤ I° or II°. Univariable and multivariable logistic regression analyses revealed predictors of residual MR ≤ I°. Long-term survival was assessed via Kaplan–Meier analysis and adjusted through propensity-score matching (PSM).

Among 821 patients, 724 (88.2%) achieved residual MR ≤ I°, whereas 97 (11.8%) achieved residual MR of II°. Patients with residual MR of II° were younger, exhibited higher morbidity, and required longer procedures with more clips. Age <65 years, prior implantable cardioverter defibrillator (ICD), and left ventricular end-diastolic diameter >62 mm served as inverse predictors of residual MR ≤ I° in univariable analysis. In contrast, only age <65 years remained a significant inverse predictor of residual MR ≤ I° in the multivariable model (odds ratio 0.39, 95% confidence interval 0.19–0.84, p = 0.01). Long-term survival did not differ significantly in the overall cohort between patients with residual MR ≤ I° and those with residual MR of II° before or after PSM.

Residual MR of II° occurred in 12% of patients and was more common in younger, comorbid individuals with complex MR anatomy. While survival was unaffected in the overall cohort, age <65 years emerged as a key predictor of suboptimal MR reduction. These findings highlight the need for critical patient selection and may inform individualized treatment strategies in contemporary mTEER practice.

*Univariable logistic regression analysis of independent predictors of residual MR ≤ I° after mTEER. ^Multivariable logistic regression analysis of the identified independent predictors of residual MR ≤ I° in the univariable logistisc regression analysis.HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular enddiastolic diameter; MR, mitral valve regurgitation; mTEER, transcatheter edge-to-edge mitral valve repair; OR, odds ratio; PSM, propensity score matching; 95%-CI, 95% confidence interval.

*Univariable logistic regression analysis of independent predictors of residual MR ≤ I° after mTEER. ^Multivariable logistic regression analysis of the identified independent predictors of residual MR ≤ I° in the univariable logistisc regression analysis.

HR, hazard ratio; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular enddiastolic diameter; MR, mitral valve regurgitation; mTEER, transcatheter edge-to-edge mitral valve repair; OR, odds ratio; PSM, propensity score matching; 95%-CI, 95% confidence interval.

## Full-text entities

- **Genes:** AMHR2 (anti-Mullerian hormone receptor type 2) [NCBI Gene 269] {aka AMHR, MISR2, MISRII, MRII}, CFH (complement factor H) [NCBI Gene 3075] {aka AHUS1, AMBP1, ARMD4, ARMS1, CFHL3, FH}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}
- **Diseases:** chronic kidney disease (MESH:D051436), valvular heart disease (MESH:D006349), FA (MESH:C565561), MR (MESH:D008944), sudden cardiac death (MESH:D016757), mitral (MESH:D008946), COPD (MESH:D029424), LVEDD (MESH:D018487), MACCEs (MESH:D002318), II (MESH:C537730), coronary artery disease (MESH:D003324), TR (MESH:D014262), Heart Failure (MESH:D006333)
- **Chemicals:** Mitra-FR (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958024/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958024/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958024/full.md

---
Source: https://tomesphere.com/paper/PMC12958024